Stock Research: Rohto Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Rohto Pharmaceutical

TSE:4527 JP3982400008
27
  • Value
    52
  • Growth
    15
  • Safety
    Safety
    33
  • Combined
    10
  • Sentiment
    63
  • 360° View
    360° View
    27
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

ROHTO PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in health and beauty care. It primarily provides eye care products (eye drops, lotions), skin care products (dermatological preparations, lip balms, sunscreens, functional cosmetics), oral medication, and food-related products (digestive medicines, Chinese herbal medicines, supplements), as well as extracorporeal test drugs. The company operates in domestic and overseas markets, including Europe, Asia, and America. In the last fiscal year, the company had 9144 employees, a market cap of $3254 million, profits of $1167 million, and revenue of $2058 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 27 (better than 27% compared with alternatives), overall professional sentiment and financial characteristics for the stock Rohto Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Rohto Pharmaceutical. The consolidated Sentiment Rank has a good rank of 63, which means that professional investors are more optimistic about the stock than for 63% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 52 or better than 52% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 33, meaning that the share price of Rohto Pharmaceutical is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 15. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 59 40 51
Growth
15 24 35 33
Safety
Safety
52 75 82 77
Sentiment
63 56 16 49
360° View
360° View
27 65 36 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
34 30 51 33
Opinions Change
68 50 6 50
Pro Holdings
n/a 96 64 97
Market Pulse
49 41 42 38
Sentiment
63 56 16 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 59 40 51
Growth
15 24 35 33
Safety Safety
52 75 82 77
Combined
10 69 56 54
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
56 62 51 49
Price vs. Earnings (P/E)
37 52 42 56
Price vs. Book (P/B)
33 34 37 59
Dividend Yield
45 52 39 31
Value
33 59 40 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
33 69 31 32
Profit Growth
51 30 53 38
Capital Growth
37 22 35 63
Stock Returns
9 41 77 53
Growth
15 24 35 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
48 69 69 66
Refinancing
45 34 47 33
Liquidity
71 77 84 82
Safety Safety
52 75 82 77

Similar Stocks

Discover high‑ranked alternatives to Rohto Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Daiwabo Holdings

TSE:3107
Country: Japan
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Sankyu

TSE:9065
Country: Japan
Industry: Trucking
Size: Medium
Full Stock Analysis

Canon Marketing Japan

TSE:8060
Country: Japan
Industry: Technology Distributors
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.